Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
(M&M Trial)

Recruiting in Palo Alto (17 mi)

+209 other locations

Overseen byGrant R Williams, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Research Team

Grant R Williams, MD

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

Newly diagnosed metastatic CRC or metastatic recurrence of CRC >= to 3 months (12 weeks) 1 year from diagnosis at age >= 60y.

Planning to or recently started to undergo undergo immunotherapy and/or 5-FU based chemotherapy as a first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan +/- immunotherapy. Capecitabine is also acceptable.

Estimated life expectancy >= 6 months.

See 3 more